Cargando…
Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study
PURPOSE: Treatment response following transarterial chemoembolization (TACE) is frequently evaluated with Liver Imaging Reporting and Data System Treatment Response (LR-TR) algorithm, but its association with patients’ outcomes is not supported in the literature. The purpose of this study was to pro...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557150/ https://www.ncbi.nlm.nih.gov/pubmed/33778924 http://dx.doi.org/10.1007/s00432-021-03603-9 |
_version_ | 1784592315267940352 |
---|---|
author | Bartnik, Krzysztof Podgórska, Joanna Rosiak, Grzegorz Korzeniowski, Krzysztof Giziński, Jakub Sajdek, Michał Wróblewski, Tadeusz Zieniewicz, Krzysztof Nyckowski, Paweł Rowiński, Olgierd |
author_facet | Bartnik, Krzysztof Podgórska, Joanna Rosiak, Grzegorz Korzeniowski, Krzysztof Giziński, Jakub Sajdek, Michał Wróblewski, Tadeusz Zieniewicz, Krzysztof Nyckowski, Paweł Rowiński, Olgierd |
author_sort | Bartnik, Krzysztof |
collection | PubMed |
description | PURPOSE: Treatment response following transarterial chemoembolization (TACE) is frequently evaluated with Liver Imaging Reporting and Data System Treatment Response (LR-TR) algorithm, but its association with patients’ outcomes is not supported in the literature. The purpose of this study was to provide such data. METHODS: A retrospective analysis of 99 TACE patients with stage A/B hepatocellular carcinoma according to Barcelona-Clinic Liver Cancer staging system was performed. Two radiologists assessed LR-TR, while a third radiologist re-assessed divergent results. Overall survival (OS) and time to disease progression (TTP) were the primary endpoints of the study, while the Cox proportional hazard model was used for outcome analyses. RESULTS: Interobserver agreement was substantial between the two readers with κ = 0.69 (95% CI 0.58–0.81). The median OS in viable, equivocal, and non-viable groups were 27, 27, and 73 months, respectively (p < 0.001). However, after adjustment for confounding factors, there was no significant association between initial viable response and OS (HR 0.98 [95% CI 0.37–2.63], p = 0.97), while equivocal response remained statistically significant (HR 3.52. [95% CI 1.27–9.71], p = 0.015). No significant association was noted when viable and equivocal groups were analyzed in aggregate (HR 1.03 [95% CI 0.4–2.4], p = 0.96). The median TTP did not differ between non-viable and viable groups (23 vs 18 months, respectively; p = 0.98). None of the analyzed predictors was associated with TTP. CONCLUSION: Initial LR-TR response was not an independent predictor for OS nor TTP. The preliminary results suggest the necessity for more aggressive management of equivocal patients. |
format | Online Article Text |
id | pubmed-8557150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-85571502021-11-15 Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study Bartnik, Krzysztof Podgórska, Joanna Rosiak, Grzegorz Korzeniowski, Krzysztof Giziński, Jakub Sajdek, Michał Wróblewski, Tadeusz Zieniewicz, Krzysztof Nyckowski, Paweł Rowiński, Olgierd J Cancer Res Clin Oncol Original Article – Clinical Oncology PURPOSE: Treatment response following transarterial chemoembolization (TACE) is frequently evaluated with Liver Imaging Reporting and Data System Treatment Response (LR-TR) algorithm, but its association with patients’ outcomes is not supported in the literature. The purpose of this study was to provide such data. METHODS: A retrospective analysis of 99 TACE patients with stage A/B hepatocellular carcinoma according to Barcelona-Clinic Liver Cancer staging system was performed. Two radiologists assessed LR-TR, while a third radiologist re-assessed divergent results. Overall survival (OS) and time to disease progression (TTP) were the primary endpoints of the study, while the Cox proportional hazard model was used for outcome analyses. RESULTS: Interobserver agreement was substantial between the two readers with κ = 0.69 (95% CI 0.58–0.81). The median OS in viable, equivocal, and non-viable groups were 27, 27, and 73 months, respectively (p < 0.001). However, after adjustment for confounding factors, there was no significant association between initial viable response and OS (HR 0.98 [95% CI 0.37–2.63], p = 0.97), while equivocal response remained statistically significant (HR 3.52. [95% CI 1.27–9.71], p = 0.015). No significant association was noted when viable and equivocal groups were analyzed in aggregate (HR 1.03 [95% CI 0.4–2.4], p = 0.96). The median TTP did not differ between non-viable and viable groups (23 vs 18 months, respectively; p = 0.98). None of the analyzed predictors was associated with TTP. CONCLUSION: Initial LR-TR response was not an independent predictor for OS nor TTP. The preliminary results suggest the necessity for more aggressive management of equivocal patients. Springer Berlin Heidelberg 2021-03-28 2021 /pmc/articles/PMC8557150/ /pubmed/33778924 http://dx.doi.org/10.1007/s00432-021-03603-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article – Clinical Oncology Bartnik, Krzysztof Podgórska, Joanna Rosiak, Grzegorz Korzeniowski, Krzysztof Giziński, Jakub Sajdek, Michał Wróblewski, Tadeusz Zieniewicz, Krzysztof Nyckowski, Paweł Rowiński, Olgierd Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study |
title | Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study |
title_full | Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study |
title_fullStr | Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study |
title_full_unstemmed | Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study |
title_short | Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study |
title_sort | performance of initial li-rads 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following tace: a retrospective, single-center cohort study |
topic | Original Article – Clinical Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557150/ https://www.ncbi.nlm.nih.gov/pubmed/33778924 http://dx.doi.org/10.1007/s00432-021-03603-9 |
work_keys_str_mv | AT bartnikkrzysztof performanceofinitiallirads2018treatmentresponseinpredictingsurvivalofpatientswithhepatocellularcarcinomafollowingtacearetrospectivesinglecentercohortstudy AT podgorskajoanna performanceofinitiallirads2018treatmentresponseinpredictingsurvivalofpatientswithhepatocellularcarcinomafollowingtacearetrospectivesinglecentercohortstudy AT rosiakgrzegorz performanceofinitiallirads2018treatmentresponseinpredictingsurvivalofpatientswithhepatocellularcarcinomafollowingtacearetrospectivesinglecentercohortstudy AT korzeniowskikrzysztof performanceofinitiallirads2018treatmentresponseinpredictingsurvivalofpatientswithhepatocellularcarcinomafollowingtacearetrospectivesinglecentercohortstudy AT gizinskijakub performanceofinitiallirads2018treatmentresponseinpredictingsurvivalofpatientswithhepatocellularcarcinomafollowingtacearetrospectivesinglecentercohortstudy AT sajdekmichał performanceofinitiallirads2018treatmentresponseinpredictingsurvivalofpatientswithhepatocellularcarcinomafollowingtacearetrospectivesinglecentercohortstudy AT wroblewskitadeusz performanceofinitiallirads2018treatmentresponseinpredictingsurvivalofpatientswithhepatocellularcarcinomafollowingtacearetrospectivesinglecentercohortstudy AT zieniewiczkrzysztof performanceofinitiallirads2018treatmentresponseinpredictingsurvivalofpatientswithhepatocellularcarcinomafollowingtacearetrospectivesinglecentercohortstudy AT nyckowskipaweł performanceofinitiallirads2018treatmentresponseinpredictingsurvivalofpatientswithhepatocellularcarcinomafollowingtacearetrospectivesinglecentercohortstudy AT rowinskiolgierd performanceofinitiallirads2018treatmentresponseinpredictingsurvivalofpatientswithhepatocellularcarcinomafollowingtacearetrospectivesinglecentercohortstudy |